Compared to Drug-sensitive TB (DS-TB), Drug-resistant TB (DR-TB) is more challenging  in terms of:​

• Cost of treatment​
• Duration of treatment​
• Higher adverse events to second-line drugs​
• Resources required by treatment providers​
• Prolonged adherence required by patients​

 Use of Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen in Special Situations

Certain drugs can be used safely while others need to be avoided along with Bedaquiline (Bdq). 

The table below provides the list of drugs that should be avoided when Bdq is part of the regimen as well as the drugs that are safe to use with Bdq.

List of Drugs that can be Used Safely or Avoided along with Bedaquiline

The anti-TB drugs recommended for treatment of Multi- and Extensively Drug-resistant (M/XDR) TB patients are grouped into three groups –  A, B and C (Figure below).

Figure: Groups A, B and C of Anti-TB Drugs used in Treatment of M/XDR-TB Patients

Second Line anti TB drugs

Figure: Summary of the Sustainable Development Goals

It is important to create a realistic Advocacy, Communication and Social Mobilisation (ACSM) budget.

General principles which would be helpful in creating a realistic budget are:

The National TB Elimination Programme (NTEP) expenditures are organised under 19 heads. These are:

1. Civil works - Initial establishment/ refurbishment costs and maintenance of civil works costs for Designated Microscopy Centres (DMC), Tuberculosis Units (TU), District TB Centres (DTC), Drug-resistant TB (DR-TB) centres and State Drug Stores (SDS).